In recent phase 3 clinical research, findings suggest that prostate cancer patients treated with brachytherapy alone receive similar outcomes to patients who received brachytherapy with additional external radiation. These findings are among recent data that show the growing power of minimally invasive brachytherapy treatment. In addition, Cesium-131 brachytherapy by Isoray has a higher average energy as well as a shorter half life than other commonly-used radioisotopes (I-125, Pd-103). The benefits of these unique attributes are a reduction in some common prostate side effects (such as urinary or sexual performance side effects), greater coverage of the prostate gland, and a reduction of the total radiation treatment time. To learn more about the benefits of Cesium-131 click here and you can read the full article below.
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose...
